CO2020001259A2 - Nuevo método para sintetizar amanitinas - Google Patents
Nuevo método para sintetizar amanitinasInfo
- Publication number
- CO2020001259A2 CO2020001259A2 CONC2020/0001259A CO2020001259A CO2020001259A2 CO 2020001259 A2 CO2020001259 A2 CO 2020001259A2 CO 2020001259 A CO2020001259 A CO 2020001259A CO 2020001259 A2 CO2020001259 A2 CO 2020001259A2
- Authority
- CO
- Colombia
- Prior art keywords
- amanitins
- synthesize
- new method
- new
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
La invención se refiere a nuevos métodos para sintetizar derivados de amanitina que tienen un grupo hidroxilo unido al resto de triptófano central. La invención se refiere además a nuevos derivados de amanitina que tienen un grupo hidroxilo unido a la posición 4', 5' o 7' del resto de triptófano central, a nuevos conjugados de tales derivados de amanitina, y a composiciones farmacéuticas que comprenden tales conjugados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17185182 | 2017-08-07 | ||
PCT/EP2018/071268 WO2019030173A1 (en) | 2017-08-07 | 2018-08-06 | NOVEL METHOD FOR SYNTHESIZING AMANITINES |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020001259A2 true CO2020001259A2 (es) | 2020-02-18 |
Family
ID=59579417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0001259A CO2020001259A2 (es) | 2017-08-07 | 2020-02-04 | Nuevo método para sintetizar amanitinas |
Country Status (14)
Country | Link |
---|---|
US (2) | US10961277B2 (es) |
EP (1) | EP3665173A1 (es) |
JP (1) | JP7165720B2 (es) |
KR (1) | KR20200037207A (es) |
CN (1) | CN111051310B (es) |
AU (1) | AU2018314668B2 (es) |
BR (1) | BR112020001345A2 (es) |
CA (1) | CA3066867A1 (es) |
CL (1) | CL2020000304A1 (es) |
CO (1) | CO2020001259A2 (es) |
MX (1) | MX2020001472A (es) |
SG (1) | SG11201912224PA (es) |
WO (1) | WO2019030173A1 (es) |
ZA (1) | ZA201908158B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110997676B (zh) | 2017-08-07 | 2022-12-20 | 海德堡医药研究有限责任公司 | 合成鹅膏蕈碱的新方法 |
JP7335260B2 (ja) * | 2017-08-18 | 2023-08-29 | バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. | 非天然アマニチン類抗体複合物 |
WO2019197654A1 (en) * | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Targeted amatoxin conjugate for the treatment of solid tumors |
KR20210102200A (ko) * | 2018-12-11 | 2021-08-19 | 하이델베르크 파마 리서치 게엠베하 | (s)-6-히드록시트립토판 및 이의 유도체의 합성 |
CA3137373A1 (en) * | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
WO2021122744A1 (en) * | 2019-12-16 | 2021-06-24 | Heidelberg Pharma Research Gmbh | Synthesis of amanin and its derivatives |
EP4161946A1 (en) * | 2020-06-09 | 2023-04-12 | Heidelberg Pharma Research GmbH | Method for synthesis of thioether-containing peptides |
CN117241832A (zh) | 2021-03-19 | 2023-12-15 | 海德堡医药研究有限责任公司 | B淋巴细胞特异性的鹅膏毒素抗体缀合物 |
CN115385916B (zh) * | 2021-07-01 | 2023-08-15 | 江苏师范大学 | 一种手性吲哚啉并吡咯化合物及其合成方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
ES2371085T3 (es) | 2006-05-27 | 2011-12-27 | Faulstich, Heinz, Dr. | Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación. |
SI3192529T1 (sl) | 2009-04-08 | 2020-07-31 | Faulstich, Heinz Dr. | Z amatoksinom ojačane vezne komponente terapevtske celične površine, zasnovane za zdravljenje tumorjev |
EP2416805B1 (en) | 2009-04-08 | 2013-07-24 | Heinz Dr. Faulstich | Amatoxin antibody conjugates for the treatment of cancer |
EP2889624B1 (en) | 2009-08-10 | 2018-10-03 | UCL Business PLC | Reversible covalent linkage of functional molecules |
ES2402254T3 (es) | 2010-09-30 | 2013-04-30 | Heidelberg Pharma Ag | Conjugados de amatoxinas con ligadores mejorados |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
US20150218220A1 (en) * | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
US20160220687A1 (en) * | 2015-02-02 | 2016-08-04 | National Guard Health Affairs | Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer |
JP6863900B2 (ja) * | 2015-03-09 | 2021-04-21 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規アマトキシン−抗体コンジュゲート |
CA3005683A1 (en) | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Research Gmbh | Derivatives of gamma-amanitin |
-
2018
- 2018-08-06 US US16/637,376 patent/US10961277B2/en active Active
- 2018-08-06 CA CA3066867A patent/CA3066867A1/en active Pending
- 2018-08-06 CN CN201880051375.7A patent/CN111051310B/zh active Active
- 2018-08-06 WO PCT/EP2018/071268 patent/WO2019030173A1/en unknown
- 2018-08-06 SG SG11201912224PA patent/SG11201912224PA/en unknown
- 2018-08-06 EP EP18746965.5A patent/EP3665173A1/en active Pending
- 2018-08-06 MX MX2020001472A patent/MX2020001472A/es unknown
- 2018-08-06 AU AU2018314668A patent/AU2018314668B2/en active Active
- 2018-08-06 BR BR112020001345-5A patent/BR112020001345A2/pt active Search and Examination
- 2018-08-06 JP JP2020506722A patent/JP7165720B2/ja active Active
- 2018-08-06 KR KR1020207000441A patent/KR20200037207A/ko active IP Right Grant
-
2019
- 2019-12-09 ZA ZA2019/08158A patent/ZA201908158B/en unknown
-
2020
- 2020-02-04 CO CONC2020/0001259A patent/CO2020001259A2/es unknown
- 2020-02-05 CL CL2020000304A patent/CL2020000304A1/es unknown
-
2021
- 2021-01-13 US US17/147,569 patent/US11702451B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20200037207A (ko) | 2020-04-08 |
CN111051310A (zh) | 2020-04-21 |
RU2020105484A (ru) | 2021-08-05 |
AU2018314668A1 (en) | 2020-01-16 |
ZA201908158B (en) | 2022-12-21 |
US20200181200A1 (en) | 2020-06-11 |
CL2020000304A1 (es) | 2020-08-07 |
RU2020105484A3 (es) | 2021-09-13 |
US10961277B2 (en) | 2021-03-30 |
SG11201912224PA (en) | 2020-01-30 |
JP2020529452A (ja) | 2020-10-08 |
JP7165720B2 (ja) | 2022-11-04 |
US20210130412A1 (en) | 2021-05-06 |
EP3665173A1 (en) | 2020-06-17 |
US11702451B2 (en) | 2023-07-18 |
AU2018314668B2 (en) | 2022-06-02 |
WO2019030173A1 (en) | 2019-02-14 |
MX2020001472A (es) | 2020-10-19 |
CN111051310B (zh) | 2022-11-08 |
CA3066867A1 (en) | 2019-02-14 |
BR112020001345A2 (pt) | 2020-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020001259A2 (es) | Nuevo método para sintetizar amanitinas | |
PH12016501693A1 (en) | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | |
PH12016501791A1 (en) | Muscarinic receptor agonists | |
EP4279071A3 (en) | Novel cannabinoid formulations | |
MX2019011926A (es) | Metodos utiles en la sintesis de analogos de halicondrina b. | |
BR112019023246A8 (pt) | melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
PH12016502524A1 (en) | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
MX2017013073A (es) | Inhibidores de grelina o-aciltransferasa. | |
EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
MX2017013072A (es) | Inhibidores de grelina o-aciltransferasa. | |
EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
IN2013MU00665A (es) | ||
ZA202002129B (en) | Oral bendamustine formulations | |
TR201714882A2 (tr) | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari | |
PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
BR112019008606A2 (pt) | inibidores de interações de mtor-deptor e métodos de uso dos mesmos | |
EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
CO2017004382A2 (es) | Composiciones farmacéuticas que comprenden lobeglitazona para administración oral | |
MX2018015269A (es) | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. | |
WO2018094035A3 (en) | Ligand ionophore conjugates | |
MX2021006533A (es) | Sintesis del (s)-6-hidroxitriptofano y derivados del mismo. |